• Je něco špatně v tomto záznamu ?

Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients

J. Obacz, V. Brychtova, J. Podhorec, P. Fabian, P. Dobes, B. Vojtesek, R. Hrstka,

. 2015 ; 8 (-) : 1523-1532. [pub] 20150624

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc15031291

Grantová podpora
NT13794 MZ0 CEP - Centrální evidence projektů

Anterior gradient protein (AGR) 3 is a highly related homologue of pro-oncogenic AGR2 and belongs to the family of protein disulfide isomerases. Although AGR3 was found in breast, ovary, prostate, and liver cancer, it remains of yet poorly defined function in tumorigenesis. This study aimed to determine AGR3 expression in a cohort of 129 primary breast carcinomas and evaluate the clinical and prognostic significance of AGR3 in these tumors. The immunohistochemical analysis revealed the presence of AGR3 staining to varying degrees in 80% of analyzed specimens. The percentage of AGR3-positive cells significantly correlated with estrogen receptor, progesterone receptor (both P<0.0001) as well as low histological grade (P=0.003), and inversely correlated with the level of Ki-67 expression (P<0.0001). In the whole cohort, AGR3 expression was associated with longer progression-free survival (PFS), whereas AGR3-positive subgroup of low-histological grade tumors showed both significantly longer PFS and overall survival. In conclusion, AGR3 is associated with the level of differentiation, slowly proliferating tumors, and more favorable prognosis of breast cancer patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031291
003      
CZ-PrNML
005      
20191021135409.0
007      
ta
008      
151005s2015 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/OTT.S82235 $2 doi
035    __
$a (PubMed)26170690
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Obacz, Joanna $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic.
245    10
$a Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients / $c J. Obacz, V. Brychtova, J. Podhorec, P. Fabian, P. Dobes, B. Vojtesek, R. Hrstka,
520    9_
$a Anterior gradient protein (AGR) 3 is a highly related homologue of pro-oncogenic AGR2 and belongs to the family of protein disulfide isomerases. Although AGR3 was found in breast, ovary, prostate, and liver cancer, it remains of yet poorly defined function in tumorigenesis. This study aimed to determine AGR3 expression in a cohort of 129 primary breast carcinomas and evaluate the clinical and prognostic significance of AGR3 in these tumors. The immunohistochemical analysis revealed the presence of AGR3 staining to varying degrees in 80% of analyzed specimens. The percentage of AGR3-positive cells significantly correlated with estrogen receptor, progesterone receptor (both P<0.0001) as well as low histological grade (P=0.003), and inversely correlated with the level of Ki-67 expression (P<0.0001). In the whole cohort, AGR3 expression was associated with longer progression-free survival (PFS), whereas AGR3-positive subgroup of low-histological grade tumors showed both significantly longer PFS and overall survival. In conclusion, AGR3 is associated with the level of differentiation, slowly proliferating tumors, and more favorable prognosis of breast cancer patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Brychtová, Veronika $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $7 xx0228678
700    1_
$a Podhorec, Ján $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $7 xx0171899
700    1_
$a Fabian, Pavel $u Department of Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. $7 xx0041823
700    1_
$a Dobeš, Petr $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $7 _AN051505
700    1_
$a Vojtěšek, Bořivoj, $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $d 1960- $7 xx0001694
700    1_
$a Hrstka, Roman $u Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic. $7 xx0077297
773    0_
$w MED00165461 $t OncoTargets and therapy $x 1178-6930 $g Roč. 8, č. - (2015), s. 1523-1532
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26170690 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20191021135842 $b ABA008
999    __
$a ind $b bmc $g 1092167 $s 914417
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 8 $c - $d 1523-1532 $e 20150624 $i 1178-6930 $m OncoTargets and therapy $n OncoTargets ther. $x MED00165461
GRA    __
$a NT13794 $p MZ0
LZP    __
$a Pubmed-20151005

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...